SCHEMBL1259902

SCHEMBL1259902

Cc1ccc(C(=O)Nc2ccc(Oc3ccc4nc(NC(=O)C5CC5)sc4n3)c(F)c2)c(=O)n1-c1ccc(F)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 13/20 0.62
KDR P35968 7/20 0.62
AXL P30530 12/20 0.51
TYRO3 Q06418 4/20 0.51
PDGFRB P09619 1/20 0.50
KIT P10721 1/20 0.50
FLT1 P17948 1/20 0.50
RIPK2 O43353 1/20 0.49
RIPK1 Q13546 1/20 0.49
RIPK3 Q9Y572 1/20 0.49
MERTK Q12866 4/20 0.48
PLK4 O00444 1/20 0.48
NTRK1 P04629 1/20 0.48
RET P07949 1/20 0.48
FLT3 P36888 1/20 0.48
MST1R Q04912 1/20 0.48
DDR1 Q08345 1/20 0.48
CAMK4 Q16566 1/20 0.48
DDR2 Q16832 1/20 0.48
MKNK1 Q9BUB5 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14949669 0.81 BRAF (0.55) METKDRPDGFRBKITFLT1
SCHEMBL1259845 0.78 MET (0.89) METKDRAXLTYRO3PDGFRB
SCHEMBL27159253 0.77 MET (0.59) METKDRAXLTYRO3RIPK2
SCHEMBL30084609 0.77 MET (0.59) METKDRAXLTYRO3RIPK2
Hydrochloric Acid SCHEMBL1259897 0.77 MET (0.89) METKDRAXLTYRO3FLT1
SCHEMBL12892687 0.77 BRAF (0.71) KDRPDGFRBKITFLT1RIPK1
SCHEMBL1260615 0.77 MET (0.69) METKDRAXLTYRO3RIPK2
SCHEMBL1260009 0.77 MET (0.69) METKDRAXLTYRO3RIPK2
SCHEMBL1258263 0.77 MET (0.63) METKDRAXLTYRO3RIPK2
Acetic Acid SCHEMBL1259623 0.76 MET (0.88) METKDRAXLTYRO3FLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8445509-B2 Fused heterocyclic derivatives and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-21 US disclosed
US-8445509-B2 Fused heterocyclic derivatives and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-21 US disclosed
US-8445509-B2 Fused heterocyclic derivatives and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-21 US disclosed
US-20110046169-A1 FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-24 US disclosed
US-20110046169-A1 FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-24 US disclosed
US-20110046169-A1 FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110046169-A1 FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF ABL1, MAP4K2, MAP3K20 MET 560/4885KDR 966/4885AXL 792/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.